✦ LIBER ✦

961 Phase I study of docetaxel and ifosfamide in patients with advanced solid tumors

✍ Scribed by L. Pronk; D. Shrijvers; D. Locci-Tonelli; J. Verweij; A.T. Van Oosterom

Book ID: 116167706
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 161 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)96210-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I study on docetaxel and ifosfamid

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumors

✍ Pronk, L.C.; Schrijvers, D.; Schellens, J.H.M.; de Bruijn, E.A.; Planting, A.S.T 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Phase I study on docetaxel and ifosfamid

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours

✍ Pronk, LC; Schrijvers, D; Schellens, JHM; de Bruijn, EA; Planting, ASTh; Locci-T 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 1014 KB

Phase I study of weekly CPT-11 (irinotec

Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors

✍ Font, A; Sanchez, J.M; Rosell, R; Taron, M; Martinez, E; Guillot, M; Manzano, J. 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Phase I study of docetaxel and topotecan

Phase I study of docetaxel and topotecan in patients with solid tumors

✍ Katherine H. Tkaczuk; William C. Zamboni; Nancy S. Tait; Barry R. Meisenberg; L. 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 103 KB

Phase I dose escalation study of docetax

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

✍ Gregory A. Masters; Bruce E. Brockstein; Sridhar Mani; Mark J. Ratain 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 69 KB

Phase I evaluation of docetaxel and topo

Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors

✍ Anne S. Tsao; Dong M. Shin; J. Lynn Palmer; Jin S. Lee; Bonnie S. Glisson 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

## Abstract ## BACKGROUND The authors administered a combination of docetaxel and topotecan with granulocyte–colony‐stimulating factor (G‐CSF) support in a Phase I study to define the maximum tolerated dose (MTD) of this regimen. ## METHODS Patients with advanced‐stage solid tumors were eligible